Expert Opinion on Investigational Drugs

MEDLINE-indexed international journal covering
drugs in early stage clinical trials and their scope for future development. (2016 IF 4.03)

[Expert Opinion on Investigational Drugs @EO_InvDrugs]

In light of the failure of Right to Try bill in The House, some background here: "Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits" https://t.co/OZeGE9GXQV by @LiaTsimberidou et al from @MDAndersonNews #rightotry #openaccess

[Richard James @RichardJames39]

Cefiderocol, a cephalosprin which targets siderophore uptake, suggested to have the potential to become first-line therapy for our most aggressive and lethal multidrug-resistant Gram-negative pathogens https://t.co/Zbhs827jL0

[Expert Opinion on Investigational Drugs @EO_InvDrugs]

Paper on discontinued #Alzheimer's drugs is particularly relevant today: "Why are they failing? Is the treatment of symptomatic dementia too late? Are the therapeutic targets incorrect? Are the clinical methodologies imprecise, misleading, or inaccurate?" https://t.co/d1OgWgUXwZ https://t.co/aO17x0rxoI

[BBC Health News @bbchealth]

Pharma giant pulls out of research into neuroscience https://t.co/xK8AnyyVJl

[Expert Opinion on Investigational Drugs @EO_InvDrugs]

Great to see @EnriqueSoto8 and @smlichtman_md's editorial "Considerations for clinical trial design in older adults with cancer" being featured in the #HemeAging session at last month's American Society of Hematology 2017 Annual Meeting #ASH17 #GeriOnc https://t.co/6DEDl4PD7U

[Kristel Gonzalez @Kristel_GT]

Agree with @MelissaLoh21 .....@EnriqueSoto8's work being highlighted during the #hemeaging session #ash17 #siog #GeriOnc #youngsiog https://t.co/C10mOjabFF …

[Mark C. Markowski @MarkowskiGUOnc]

BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations https://t.co/fmWkkj9pYd

[Expert Opinion on Investigational Drugs @EO_InvDrugs]

Endoglin and ALK1 as therapeutic targets for hereditary hemorrhagic telangiectasia written by Ruiz-Llorente et al (@CIBERER) is Open Access and available here at Expert Opinion on Therapeutic Targets: https://t.co/TO34zvkGu2

[Expert Opinion on Investigational Drugs @EO_InvDrugs]

Interesting perspective on an emerging field - Investigational PD-1 inhibitors for advanced non-small lung cancer, new players in a shifting paradigm. Free to read editorial by Ghanem et al from @NorthwellHealth, available here: https://t.co/YC8bqZvRuc

[Expert Opinion on Investigational Drugs @EO_InvDrugs]

Editorial by @EnriqueSoto8 & @smlichtman_md - "Considerations for clinical trial design in older adults with cancer" is free to view online! https://t.co/6np3YbK2TZ

[Enrique Soto @EnriqueSoto8]

An honor to write this editorial w/ @SIOGorg pres @smlichtman_md @ExpertOpinion on Investigational Drugs! #gerionc https://t.co/AeQAd4aZin

[Expert Opinion on Investigational Drugs @EO_InvDrugs]

BI 695502, US- & EU-approved Avastin showed 3-way bioequivalence with similar safety profile. Free access to trial - https://t.co/dNXPYqoEPe

[Pain in Motion @PaininMotion]

SLEEP disturbances & severe STRESS as GLIAL activators: psychoneuroimmunology model explaining central sensitization https://t.co/kCiFzQFhGn

[Expert Opinion on Investigational Drugs @EO_InvDrugs]

Phase I trial assessing the bioequivalence of BI 695502, a bevacizumab biosimilar candidate. Free to access - https://t.co/dNXPYqoEPe

[Expert Opinion on Investigational Drugs @EO_InvDrugs]

Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015 https://t.co/K05V1hpAOb

[Expert Opinion on Investigational Drugs @EO_InvDrugs]

Review - Preclinical to Phase II Amyloid beta (Aβ) peptide modulators under investigation for Alzheimer’s disease https://t.co/FQGkuwjsGy

[Expert Opinion on Investigational Drugs @EO_InvDrugs]

Review article - MERS-CoV spike protein: a key target for antivirals. Free to view until end of April. https://t.co/3tk5EmVjiq

[Expert Opinion on Investigational Drugs @EO_InvDrugs]

Read about accessory gene regulator-1 as a therapeutic target for C. difficile infection in this free editorial: https://t.co/RXKigP2vTZ

[Expert Opinion on Investigational Drugs @EO_InvDrugs]

Review article - Drugs in clinical development for the treatment of amyotrophic lateral sclerosis (ALS) https://t.co/ztiYyTKrd0

[Expert Opinion on Investigational Drugs @EO_InvDrugs]

@TheScientistLLC The MERS-CoV spike protein review that is referred to in this article is free to access for April! https://t.co/3tk5EmVjiq https://t.co/J0mzj45lwM

[The Scientist @TheScientistLLC]

Experimental MERS treatments target host cells' DPP-4 receptors. https://t.co/DqoSuIp5AN

[Expert Opinion on Investigational Drugs @EO_InvDrugs]

Read about the latest investigational drugs for head and neck #cancer in this recently published #free #editorial https://t.co/YANLP4lTuJ

[Expert Opinion on Investigational Drugs @EO_InvDrugs]

An interesting new review recently published in Expert Opinion on Therapeutic Targets https://t.co/1tg4EG4lr1

[Expert Opinion on Investigational Drugs @EO_InvDrugs]

Read this #free to view #editorial on KCC3 cotransporter as a therapeutic target for peripheral neuropathy... https://t.co/hKQIZOdhOV